Immunohistochemical Studies of the Kynurenine Pathway in Morphea

International Journal of Tryptophan Research

Volumn 6, Issue , 2013, Pages

  Noakes, Rowland ^a   Mellick, Nick ^b  

^a Queensland Institute of Dermatology and Veracity Clinical Research   (Australia)

^b Zenith Specialist Pathology   (Australia)

Author keywords

indoleamine 2,3 dioxygenase; Morphea; quinolinic acid

Indexed keywords

EID: 84926644929     PISSN: None     EISSN: 11786469     Source Type: Journal    
DOI: 10.4137/IJTR.S13371     Document Type: Article

References (40)

1. Freundlich B., Werth V.P., Rook A.H. et al. L-tryptophan ingestion associated with eosinophilic fasciitis but not progressive systemic sclerosis. Ann Intern Med. 1990; 112(10): 758–62.
2. Grigoris I., de Launey W., Jevtic A.P. Eosinophilic fasciitis associated with L-tryptophan ingestion. Med J Aust. 1992 Sep 7; 157(5): 329–30.
3. Martin R.W., Duffy J., Engel A.G. et al. The clinical spectrum of the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion. Clinical features in 20 patients and aspects of pathophysiology. Ann Intern Med. 1990; 113(2): 124–34.
4. Mayeno A.N., Lin F., Foote C.S. et al. Characterization of “peak E,” a novel amino acid associated with eosinophilia-myalgia syndrome. Science. 1990; 250(4988): 1707–8.
5. Blauvelt A., Falanga V. Idiopathic and L-tryptophan-associated eosinophilic fasciitis before and after L-tryptophan contamination. Arch Dermatol. 1991; 127(8): 1159–66.
6. Silver R.M., McKinley K., Smith E.A. et al. Tryptophan metabolism via the kynurenine pathway in patients with the eosinophilia-myalgia syndrome. Arthritis Rheum. 1992; 35(9): 1097–105.
7. Silver R.M., Sutherland S.E., Carreira P., Heyes M.P. Alterations in tryptophan metabolism in the toxic oil syndrome and in the eosinophilia-myalgia syndrome. J Rheumatol. 1992; 19(1): 69–73.
8. Noakes R., Spelman L., Williamson R. Is the L-tryptophan metabolite quinolinic acid responsible for eosinophilic fasciitis? Clin Exp Med. 2006; 6(2): 60–4.
9. Nahm W.K., Philpot B.D., Adams M.M. et al. Significance of N-methyl-D-aspartate (NMDA) receptor-mediated signaling in human keratinocytes. J Cell Physiol. 2004; 200(2): 309–17.
10. Asp L., Johansson A.S., Mann A. et al. Effects of pro-inflammatory cytokines on expression of kynurenine pathway enzymes in human dermal fibroblasts. J Inflamm (Lond). 2011; 8: 25.
11. Guillemin G.J., Brew B.J. Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification. J Leukoc Biol. 2004; 75(3): 388–97.
12. Fujigaki H., Saito K., Lin F. et al. Nitration and inactivation of IDO by peroxynitrite. J Immunol. 2006; 176(1): 372–9.
13. Moffett J.R., Namboodiri M.A. Tryptophan and the immune response. Immunol Cell Biol. 2003; 81(4): 247–65.
14. Yasui H., Takai K., Yoshida R., Hayaishi O. Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients. Proc Natl Acad Sci USA. 1986; 83(17): 6622–6.
15. Dai W., Gupta S.L. Regulation of indoleamine 2,3-dioxygenase gene expression in human fibroblasts by interferon-gamma. Upstream control region discriminates between interferon-gamma and interferon-alpha. J Biol Chem. 1990; 265(32): 19871–7.
16. Marttila S., Jylhävä J., Eklund C., Hervonen A., Jylhä M., Hurme M. Aging-associated increase in indoleamine 2,3-dioxygenase (IDO) activity appears to be unrelated to the transcription of the IDO1 or IDO2 genes in peripheral blood mononuclear cells. Immun Ageing. 2011; 8: 9.
17. Meyer K.C., Klatte J.E., Dinh H.V. et al. Evidence that the bulge region is a site of relative immune privilege in human hair follicles. Br J Dermatol. 2008; 159(5): 1077–85.
18. Wang Y., Liu H., McKenzie G. et al. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med. 2010; 16(3): 279–85.
19. Brown R.R., Ozaki Y., Datta S.P., Borden E.C., Sondel P.M., Malone D.G. Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv Exp Med Biol. 1991; 294: 425–35.
20. Pfefferkorn E.R. Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sci USA. 1984; 81(3): 908–12.
21. Lee G.K., Park H.J., Macleod M., Chandler P., Munn D.H., Mellor A.L. Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology. 2002; 107(4): 452–60.
22. Munn D.H., Sharma M.D., Baban B. et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity. 2005; 22(5): 633–42.
23. Fallarino F., Grohmann U., Vacca C. et al. T cell apoptosis by kynurenines. Adv Exp Med Biol. 2003; 527: 183–90.
24. Metz R., Duhadaway J.B., Kamasani U., Laury-Kleintop L., Muller A.J., Prendergast G.C. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 2007; 67(15): 7082–7.
25. Salter M., Pogson C.I. The role of tryptophan 2,3-dioxygenase in the hormonal control of tryptophan metabolism in isolated rat liver cells. Effects of glucocorticoids and experimental diabetes. Biochem J. 1985: 229(2): 499–504.
26. Fallarino F., Grohmann U., Vacca C. et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 2002; 9(10): 1069–77.
27. Platten M., Ho P.P., Youssef S. et al. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science. 2005; 310(5749): 850–5.
28. Moroni F., Russi P., Lombardi G., Beni M., Carlà V. Presence of kynurenic acid in the mammalian brain. J Neurochem. 1988; 51(1): 177–80.
29. Jhamandas K., Boegman R.J., Beninger R.J. Balik M. Quinolinate-induced cortical cholinergic damage: modulation by tryptophan metabolites. Brain Res. 1990; 529(1-2): 185–91.
30. Kim J.P., Choi D.W. Quinolinate neurotoxicity in cortical cell culture. Neuroscience. 1987; 23(2): 423–32.
31. Christen-Zaech S., Hakim M., Afsar S., Paller A. Pediatric morphea (localized scleroderma): Review of 136 patients. J Am Acad Dermatol. 2008; 59: 385–96.
32. Stone T.W., Perkins M.N. Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol. 1981; 72: 411–2.
33. Zulian F., Vallongo C., Woo P., Russo R., Ruperto N. et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum. 2005 Sep; 52(9): 2873–81.
34. Sekkai D., Guittet O., Lemaire G., Tenu J.P., Lepoivre M. Inhibition of nitric oxide synthase expression and activity in macrophages by 3-hydroxyanthranilic acid, a tryptophan metabolite. Arch Biochem Biophys. 1997; 340: 117–23.
35. Killoran C., Falanga V. Morphea. Dermatology in General Medicine. 7th Ed. Pp 543.
36. Lawrence D.A. Transforming growth factor-beta: a general review. Eur Cytokine Netw. 1996 Sep; 7(3): 363–74.
37. Belladonna M.L., Orabona, Grohmann U., and Puccetti P. TGF-β and kynurenines as the key to infectious tolerance. Trends in Molecular Medicine. January 21, 2009; 15(2): 41–9.
38. Pawlak K., Mysliwiec M., Pawlak D. 2. Haemostatic system, biochemical profiles, kynurenines and the prevalence of cardiovascular disease in peritoneally dialyzed patients Thromb Res. 2010 Feb; 125(2): e40–5. Epub September 3, 2009.
39. Guillemin G.J. et al. Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol Appl Neurobiol. 2005; 31(4): 395–404.
40. Taniguchi S., Yorifuji T., Hamada T. Treatment of linear localized scleroderma with the anti-allergic drug, tranilast. Clin Exp Dermatol. 1994 Sep; 19(5): 391–3.